Am J OphthalmolOctober 2022Published Erratum
Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.
Authors
Gala Beykin, Laurel Stell, Muhammad Sohail Halim, Mariana Nuñez, Lilia Popova, Bac T Nguyen, Sylvia L Groth, Amy Dennis, Zhongqiu Li, Melissa Atkins, Tom Khavari, Sophia Y Wang, Robert Chang, Ann C Fisher, Yasir J Sepah, Jeffrey L Goldberg
No abstract available for this article.
More by Gala Beykin
View full profile →Discovery and clinical translation of novel glaucoma biomarkers.
2021Prog Retin Eye Res69 citations
Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.
2022Am J Ophthalmol33 citations
Structural and Metabolic Imaging After Short-term Use of the Balance Goggles System in Glaucoma Patients: A Pilot Study.
2022J Glaucoma6 citations
Discussion
Comments and discussion will appear here in a future update.